The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Deferiprone (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 13 Apr 2016 According to ClinicalTrials.gov, status changed from not yet recruiting to recruiting.